TG Therapeutics, Inc.
TGTX
$33.59
$0.190.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 11.71% | 28.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.71% | 28.98% | |||
| Cost of Revenue | 0.92% | 64.85% | |||
| Gross Profit | 13.50% | 24.48% | |||
| SG&A Expenses | 29.18% | -7.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 43.46% | 9.51% | |||
| Operating Income | -71.21% | 140.86% | |||
| Income Before Tax | -78.52% | 496.37% | |||
| Income Tax Expenses | -80.77% | 446.91% | |||
| Earnings from Continuing Operations | -78.31% | 501.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -78.31% | 501.31% | |||
| EBIT | -71.21% | 140.86% | |||
| EBITDA | -71.19% | 140.72% | |||
| EPS Basic | -78.52% | 501.50% | |||
| Normalized Basic EPS | -78.72% | 495.11% | |||
| EPS Diluted | -79.97% | 649.00% | |||
| Normalized Diluted EPS | -78.85% | 498.19% | |||
| Average Basic Shares Outstanding | 0.99% | 0.10% | |||
| Average Diluted Shares Outstanding | 1.58% | -0.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||